HEREDITARY ANGIOEDEMA (HAE) BENEFITS VERIFICATION CHECKLIST

TAKHZYRO® (lanadelumab-flyo) injection

No matter where you are in the benefits investigation process—whether it's submitting a prior authorization or appealing a claim denial—here is the information we suggest keeping on hand.

- ☐ **ICD-10 code D84.1**
- ☐ **Lab tests used to confirm an HAE diagnosis[1]***
  - Serum C4
  - C1-INH function
  - C1 esterase inhibitor (C1-INH) antigen

  *Some payers require complement component 4 (C4) and/or C1q tests to be submitted.
- ☐ **Patient's family medical history**
- ☐ **Attack history and relevant characteristics** *(eg, location, severity, and frequency)*
- ☐ **HAE-related hospitalizations, ER visits, and intubations**
- ☐ **Treatments** *(both current and previous)*
- ☐ **Photos of HAE attacks** *(to help payers understand the severity and impact of HAE for that patient)*

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Please see additional Important Safety Information throughout and full Prescribing Information.

TAKHZYRO®
(lanadelumab-flyo) injection

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and full Prescribing Information.

Reference: 1. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. *J Allergy Clin Immunol Pract.* 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046

Takeda

US-LANA-1871v1.0 05/23